A Prospective Study of EUS Guided Celiac Block

Indiana University

Status: Completed

Conditions: Chronic Pancreatitis; Pancreatic Cancer

Treatments: Drug: 98% dehydrated alcohol; Drug: triamcinolone

Study type: Observational

Funder types: Other

Identifiers

NCT00583271

0205-04B

IRB #0205-04B

Details and patient eligibility

About

The purpose of this prospective study is to measure the clinical effectiveness of EUS-guided CB in subjects, 50 who have chronic pancreatitis and 50 who have pancreatic cancer, that are already undergoing celiac block for clinical reasons.

Enrollment: 127 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients with chronic abdominal pain from documented chronic pancreatitis or pancreatic cancer or other visceral malignancy that are undergoing EUS-guided CB (for purposes other than this study) will be eligible to participate in this study.
• Patients with chronic pancreatitis and pancreatic cancer must have documented disease by CT, ERCP, or EUS.
• No evidence of dementia or altered mental status that would prohibit the giving and understanding of informed consent, and no evidence of psychiatric risk that would preclude adequate compliance with this protocol.
• Patient must provide signed written informed consent

Exclusion criteria

• Patients that have had a previous celiac plexus block are eligible for this study

Trial design

127 participants in 2 patient groups

1

Description:

subjects who are getting a celiac block for chronic pancreatitis

Treatment:

Drug: triamcinolone

2

Description:

subjects who are getting a celiac block for pancreatic cancer

Treatment:

Drug: 98% dehydrated alcohol